Winther K, Rein E, Hedman C
Department of Clinical Biochemistry, University Hospital of Copenhagen in Gentofte, Hellerup, Denmark.
Climacteric. 2005 Jun;8(2):162-70. doi: 10.1080/13697130500117987.
The fact that hormone replacement therapy has been claimed to increase the risk of breast cancer has made it relevant to search for new non-hormonal treatments of menopausal symptoms.
This study aimed to evaluate whether Femal, a herbal remedy made from pollen extracts, alleviates the symptoms of the menopause, especially hot flushes.
A randomized, double-blind, placebo-controlled, parallel trial of 64 menopausal women, of whom 54 completed the trial. After an initial run-in phase of 1 month, the women were randomly given either two Femal tablets each morning, or two identical placebo tablets, for 3 months of treatment. On inclusion, and then at 4-week intervals, the patients were asked to evaluate 16 symptoms of the menopause using Menopause Rating Scales (MRS). In addition, every day throughout the study, certain menopausal symptoms were recorded in a diary.
The two treatment groups were identical regarding demographic data and the initial symptom scores. In the active-treatment group, 65% responded with a reduction in hot flushes compared with 38% in the placebo group (p<0.006) and, in this group, the number of hot flushes registered in diaries declined after 3 months by 27% as compared to the placebo group (p<0.026). MRS evaluation of hot flushes yielded similar results (p<0.031). There were 23% and 22% decreases in hot flushes after 2 and 3 months of treatment, respectively, and after both intervals of time the inter-group comparisons were significantly affected. An overall evaluation of the trend in 15 other 'quality-of-life' parameters showed likewise in favor of the pollen extract (p<0.031).
The pollen extract Femal significantly reduces hot flushes and certain other menopausal symptoms when compared to placebo.
激素替代疗法被认为会增加患乳腺癌的风险,这使得寻找新的非激素疗法来治疗更年期症状变得很有必要。
本研究旨在评估一种由花粉提取物制成的草药制剂Femal是否能缓解更年期症状,尤其是潮热。
一项针对64名更年期女性的随机、双盲、安慰剂对照平行试验,其中54名女性完成了试验。在最初1个月的导入期后,这些女性被随机分配,每天早晨服用两片Femal片或两片相同的安慰剂片,进行为期3个月的治疗。纳入研究时以及之后每隔4周,要求患者使用更年期评定量表(MRS)评估16种更年期症状。此外,在整个研究过程中,每天将某些更年期症状记录在日记中。
两个治疗组在人口统计学数据和初始症状评分方面相同。在活性治疗组中,65%的患者潮热症状减轻,而安慰剂组为38%(p<0.006),且在该组中,日记中记录的潮热次数在3个月后比安慰剂组减少了27%(p<0.026)。对潮热的MRS评估也得出了类似结果(p<0.031)。治疗2个月和3个月后,潮热分别减少了23%和22%,且在这两个时间间隔后,组间比较均受到显著影响。对其他15个“生活质量”参数趋势的总体评估同样显示花粉提取物更具优势(p<0.031)。
与安慰剂相比,花粉提取物Femal能显著减轻潮热及其他一些更年期症状。